A structured tapering plan, combined with healthy habits, is essential for maintaining progress after stopping GLP-1 therapy
Conclusion Key Takeaways Semaglutide & Tirzepatide offer revolutionary options for weight loss and diabetes management
Because of this, switching requires clinical oversight to reduce the risk of side effects and ensure the new treatment is suitable for you
WEGOVY- semaglutide injection, solution WEGOVY- semaglutide tablet Novo Nordisk Pharmaceutical Industries, LP ---------- WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended
Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss this with their prescriber as a precaution
In the SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1 mg for type 2 diabetes, nausea rates were 17-22% for tirzepatide across all three dose levels (5 mg, 10 mg, and 15 mg) versus 18% for semaglutide 1 mg
